4-氨基噻吩并[3,2-D]嘧啶 | 16285-74-8

• 物质功能分类: 医药中间体 - 杂环化合物 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并嘧啶酮衍生物
• 中文名称: 4-氨基噻吩并[3,2-D]嘧啶
• 中文别名: 噻吩并[3,2-d]嘧啶-4-胺
• 英文名称: thieno[3,2-d]pyrimidin-4-amine
• 英文别名: thieno[3,2-d]pyrimidin-4-ylamine；4-aminothieno[3,2-d]pyrimidine；4-Amino-thieno<3,2-d>pyrimidin；4-Amino<3,2d>thienopyrimidin
• CAS: 16285-74-8
• 化学式: C₆H₅N₃S
• mdl: MFCD09834952
• 分子量: 151.192
• InChiKey: QIZMFTNGJPBSBT-UHFFFAOYSA-N

物化性质

• 熔点：
  226 °C
• 沸点：
  346.8±22.0 °C(Predicted)
• 密度：
  1.485±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于乙腈（少许）、DMSO（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  80
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Thieno[3,2-d]pyrimidin-4-amine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Thieno[3,2-d]pyrimidin-4-amine
CAS number: 16285-74-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H5N3S
Molecular weight: 151.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-氨基噻吩并[3,2-D]嘧啶 在 palladium 10% on activated carbon 、 氢气 、 palladium diacetate 、 caesium carbonate 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 作用下， 以 甲醇 、 二氯甲烷 、 甲苯 为溶剂， 反应 8.0h， 生成 1-(4-chloro-3-(trifluoromethyl)phenyl)-3-(2-(thieno[3,2-d]pyrimidin-4-ylamino)pyridin-3-yl)urea
  参考文献：
  名称：

  新型KDR激酶抑制剂1-（4-氯-3-（三氟甲基）-苯基）-3-（2-（氨基）吡啶-3-基）脲的发现和优化

  摘要：

  激酶插入物含域受体（KDR）是抗癌药物发现和开发的当前验证目标之一。在此，已经合成了一系列邻氨基-芳基脲衍生物，并评估了它们的激酶抑制活性。在生物学筛选和分子建模的基础上进行优化，与该命中化合物相比，可明显提高KDR激酶的抑制活性。最终，我们确定了针对KDR的1-（4-氯-3-（三氟甲基）苯基）-3-（2-（（喹啉-4-基甲基）氨基）吡啶-3-基）脲支架的有效抑制剂5a（ IC 50 = 0.0689 µM），可以作为进一步优化KDR抑制剂和开发的良好起点。

  DOI：

  10.2174/1573406412666151215105149
• 作为产物：
  描述：

  4-氯噻吩并[3,2-d]嘧啶 在 ammonium hydroxide 作用下， 以 乙醇 为溶剂， 反应 8.0h， 以81.4%的产率得到4-氨基噻吩并[3,2-D]嘧啶
  参考文献：
  名称：

  新型KDR激酶抑制剂1-（4-氯-3-（三氟甲基）-苯基）-3-（2-（氨基）吡啶-3-基）脲的发现和优化

  摘要：

  激酶插入物含域受体（KDR）是抗癌药物发现和开发的当前验证目标之一。在此，已经合成了一系列邻氨基-芳基脲衍生物，并评估了它们的激酶抑制活性。在生物学筛选和分子建模的基础上进行优化，与该命中化合物相比，可明显提高KDR激酶的抑制活性。最终，我们确定了针对KDR的1-（4-氯-3-（三氟甲基）苯基）-3-（2-（（喹啉-4-基甲基）氨基）吡啶-3-基）脲支架的有效抑制剂5a（ IC 50 = 0.0689 µM），可以作为进一步优化KDR抑制剂和开发的良好起点。

  DOI：

  10.2174/1573406412666151215105149

文献信息

• Therapy
  申请人：——

  公开号：US20030225111A1

  公开（公告）日：2003-12-04

  The invention concerns the use of a quinazoline derivative of Formula (I) wherein Q 1 includes a quinazoline ring optionally substituted with a group such as halogeno, trifluoromethyl and cyano, or a group of the formula: Q 3 —X 1 — wherein X 1 includes a direct bond and O and Q 3 includes aryl, aryl-(1-6C)alkyl, heterocyclyl and heterocyclyl-(1-6C)alkyl; each of R 2 and R 3 is hydrogen or (1-6C)alkyl; Z includes O, S and NH; and Q 2 includes aryl and aryl-(1-3C)alkyl or a pharmaceutically-acceptable salt thereof, in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human. 1

  该发明涉及使用式（I）的喹唑啉衍生物，其中Q1包括一个喹唑啉环，可选地取代为卤、三氟甲基和氰等基团，或者具有式Q3-X1-的基团，其中X1包括直接键和O，Q3包括芳基、芳基-(1-6C)烷基、杂环基和杂环基-(1-6C)烷基；R2和R3中的每一个是氢或(1-6C)烷基；Z包括O、S和NH；Q2包括芳基和芳基-(1-3C)烷基或其药用可接受盐，在制备药物时用于在温血动物（如人类）中产生抗血管生成和/或降低血管通透性的效果。
• [EN] SUBSTITUTED TETRAHYDROPYRIDOTHIENOPYRIMIDINES<br/>[FR] TÉTRAHYDROPYRIDOTHIÉNOPYRIMIDINESSUBSTITUÉES
  申请人：BAYER PHARMA AG

  公开号：WO2015181063A1

  公开（公告）日：2015-12-03

  The present invention relates to substituted tetrahydropyridothienopyrimidine compounds of general formula(I)as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.

  本发明涉及一般式(I)所述的取代四氢吡啶噻吡嘧啶化合物，以及制备该化合物的方法，用于制备该化合物的有用中间体化合物，包含该化合物的药物组合物和组合物，以及利用该化合物制造用于治疗或预防疾病的药物组合物，特别是用作唯一药剂或与其他活性成分组合使用，治疗或预防过度增殖和/或血管生成障碍。
• [EN] SUBSTITUTED PYRROLOPYRIMIDINYLAMINO-BENZOTHIAZOLONES AS MKNK KINASE INHIBITORS<br/>[FR] PYRROLOPYRIMIDINYLAMINOBENZOTHIAZOLONES SUBSTITUÉES COMME INHIBITEURS DE MKNK KINASE
  申请人：BAYER PHARMA AG

  公开号：WO2014044691A1

  公开（公告）日：2014-03-27

  The present invention relates to substituted pyrrolopyrimidinylamino-benzothiazolone compounds of general formula I as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.

  本发明涉及一般式I所述的取代吡咯吡嘧啶基氨基苯并噻唑酮化合物，以及制备该化合物的方法，用于制备该化合物的有用中间体化合物，包含该化合物的药物组合物和药物组合物，以及利用该化合物制造用于治疗或预防疾病的药物组合物，特别是用作唯一药剂或与其他活性成分组合使用，用于治疗或预防过度增殖和/或血管生成紊乱的疾病。
• [EN] SUBSTITUTED PYRAZOLO-PYRIDINAMINES<br/>[FR] PYRAZOLO-PYRIDINAMINES SUBSTITUÉES
  申请人：BAYER PHARMA AG

  公开号：WO2015004024A1

  公开（公告）日：2015-01-15

  The present invention relates to substituted pyrazolopyridine compounds of general formula I as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.

  本发明涉及通式I所述和定义的取代吡唑吡啶化合物，涉及制备所述化合物的方法，用于制备所述化合物的有用中间体化合物，包含所述化合物的药物组合物和复合物，以及利用所述化合物制造用于治疗或预防疾病的药物组合物，特别是治疗或预防过度增殖和/或血管生成紊乱的疾病，作为唯一药剂或与其他活性成分组合使用。
• [EN] THIENOPYRIMIDINES AS MKNK1 AND MKNK2 INHIBITORS<br/>[FR] THIÉNOPYRIMIDINES EN TANT QU'INHIBITEURS DE MKNK1 ET DE MKNK2
  申请人：BAYER PHARMA AG

  公开号：WO2015074986A1

  公开（公告）日：2015-05-28

  The present invention relates to substituted thienopyrimidine compounds of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.

  本发明涉及通式（I）所述的取代噻吩嘧啶化合物，以及制备该化合物的方法，用于制备该化合物的有用中间体化合物，包含该化合物的药物组合物和组合物，以及使用该化合物制造用于治疗或预防疾病的药物组合物，特别是用作唯一药剂或与其他活性成分结合。